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Abstract 
Background: Monomethyl auristatin E (MMAE) is a synthetic analog of dolastatin 10, a compound originally 
isolated from the marine mollusk. MMAE, as a highly potent microtubule inhibitor, exerts its potent cytotoxic 
effect by inhibiting microtubule assembly, tubulin-dependent GTP hydrolysis and microtubes polymerization. 
This molecule, by itself, lacks the tumor specificity required to elicit therapeutic benefit. Nevertheless, the 
extremely cytotoxic potential of MMAE could be harnessed in the form of MMAE-antibody conjugates. The 
aim of the present study was to evaluate the cytotoxic activity of MMAE against breast (SKBR3) and kidney 
(HEK293) cancer cell lines in an in vitro cell-based assay. 
Materials and Methods: SKBR3 and HEK293 cells were treated with different concentrations ranging from 
0.002048, 0.01024, 0.0512, 0.256, 1.28, 6.4, 32, 160, 800 and 4000 nM of MMAE, and cell viability was 
determined after 72 hours using an MTT colorimetric assay. The effect of MMAE was regularly monitored by 
direct observation using an invert microscope. 
Results: Microscopic observation showed that there was a concentration-dependent increase in cell death. 
Results from the MTT assay revealed a statistically significant loss of viability (P<0.0001) at concentrations 
ranging from 0.01024 to 4000 nM in SKBR3 cells, and 0.0512 to 4000 nM in HEK293 cells. Our findings 
showed that MMAE inhibited the growth of SKBR3 and HEK293 cells in a concentration-dependent 
manner, with IC50 values of 3.27 ± 0.42 and 4.24 ± 0.37 nM, respectively. 
Conclusion: MMAE was able to significantly inhibit cell growth at nanomolar concentrations, emphasizing its 
great potential for the development of antibody-drug conjugates. 
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Introduction 
Dolastatins are natural cytotoxic pseudopeptides, 
which were first isolated from the small Indian Ocean 
sea hare Dollabella auricularia. The dolastatin family 
includes cemadotin, tasidotin (ILX651), soblidotin, 
malevamide E and dolastatin 10
1,2
. Dolastatin 10 has 
demonstrated potent activity in preclinical studies 
against a range of lymphomas, leukemia and solid 
tumors
3,4
. As a potent disruptor of tubulin 
polymerization
5
, dolastatin 10 inhibits the binding of 
Vinca alkaloids to tubulin in a noncompetitive 
fashion, and stabilize the binding of colchicines to 
tubulin. This potent antitumor agent, in addition to 
tubulin polymerization inhibition, has a strong 
inhibitory effect on tubulin dependent GTP 
hydrolysis
6
, which can serve as an extremely potent 
mitotic spindle poison
7
. Dolastatin 10 consists of a 
four amino acid peptide (dolavaline, valine, 
dolaisoleuine, dolaproine) linked to a complex 
primary amine (dolaphenine), showing a potent 
cytotoxic activity at nanomolar concentrations
5
. 
Although the dolaisoleuine amino acid residue is 
critical for the inhibition of tubulin polymerization, 
the dolaproine or dolavaline amino acids can be 




Because it is difficult to extract large quantities of 
dolastatin 10, efforts have resulted in the development 
of the potent synthetic dolastatin 10 analogs, termed 
auristatin, including Monomethyl auristatin F 
(MMAF) and Monomethyl auristatin E (MMAE). 





 M) developed by Seattle Genetics. This 
cytotoxic molecule represents as much as 100 to 1000 
folds more potent than the standard chemotherapeutic 
drugs such as vinblastine
10,11
. However, MMAE, as 
well as MMAF, is currently being used as payloads in 
antibody-drug conjugates (ADCs), showing excellent 




Importantly, an MMAE-antibody conjugate 
brentuximab vedotin (Adcetris®) has already been 
approved by the US Food and Drug Administration 
(FDA) for clinical use
18
. 
Some studies evaluated the cytotoxic activity of 
auristatnes on a diverse panel of human tumor cell 
lines including hematological malignancies, 
melanoma, and carcinomas of the lung, stomach, 
prostate, ovaries, pancreas, breast, colon and kidneys, 
and compared with the activities of another 
antimitotic agent, vinblastine, as well as to 
doxorubicin
19,20
. However, there are no reports 
specifically examining the effect of MMAE on 
SKBR3 and HEK293 cell lines. Therefore, we sought 
to investigate the anticancer activity of MMAE and to 
determine the minimum effective dose in SKBR3 and 
HEK293 cells using an in vitro model. In the present 
study, the cells were exposed to various 
concentrations of MMAE and the growth response 
was measured in a dose-dependent manner. Cell 
viability was determined using the MTT assay. The 
findings from this study demonstrated potent 
cytotoxic activity of MMAE on human cancer cell 
lines SKBR3 and HEK293. 
Methods 
Cell Lines and Culture: SkBR3 (human breast 
cancer cell line) and HEK-293 (human embryonic 
kidney cell line) were purchased from National Cell 
Bank of Iran (Pasteur Institute of Iran, Tehran, Iran). 
Cells were cultured in high-glucose Dulbecco's 
Mmodified Eagle's Medium (DMEM; Sigma-Aldrich) 
supplemented with 10% heat inactivated fetal bovine 
serum (FBS), 100 unit/ml penicillin, 100 μg/ml 
streptomycin and 0.2 mM Glotamax (Invitrogen 
Gibco), with 5% CO2 and 95% humidity at 37°C. At 
approximately 80% confluency, the cells were 
detached by trypsin-EDTA (Sigma, St Louis, MO) 
and cell numbers were counted using a Neubauer 
hemocytometer
21
. Cell viability was estimated to be 
95%. 
MMAE preparation: MMAE was purchased from 
Concortis Biosystems (Corp, San Diego, CA, USA). 
The drug was stored at -20 until used. The solutions 
of MMAE were prepared and vigorously stirred 
before dilution in the filtered cell culture medium and 
stored at −20˚C. The stock solution was then serially 
diluted with the medium to obtain working solutions. 
The drug concentration range used in this study was 
approximately the same as that reported in literature
22
. 
Cell cytotoxicity assay: In vitro cell cytotoxicity was 
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HEK293 cells, respectively, were cultivated in 96-
well tissue culture plates (Greiner, Frickenhausen, 
Germany) with or without the drug MMAE in a final 
volume of 200 μl, as triplicates. The plating density 
and assay time course were optimized for each cell 
line. MMAE was added approximately 24 hours after 
cell seeding. At 80% confluency, the cells were 
treated with MMAE at various concentrations 
(0.002048, 0.01024, 0.0512, 0.256, 1.28, 6.4, 32, 160, 
800 and 4000 nM). Untreated cells were used as a 
negative control. After a 72-hour incubation, the 
medium was aspirated, cells were washed twice with 
PBS, and 100 μl/well MTT (3-(4,5-Dimethylthiazol-
2-yl)-2,5-Diphenyltetrazolium Bromide) solution 
(Sigma-Aldrich, 5 mg/mL in PBS) was added to each 
well; the cells were then incubated for 4 hours at 
37°C. After the incubation period, the media was 
aspirated, and the formazan crystals in cells were 
dissolved in 200 μl of dimethyl sulphoxide (DMSO, 
Sigma Aldrich, USA). Afterwards, the plates were 
incubated on a rotary shaker at 37°C for 1 hour to 
solubilize the formations of purple crystal formazan. 
The absorbance was measured using a microplate 
reader at a wavelength of 570 nm. The absorbance of 
untreated cells was considered to be 100% survival. 
The cytotoxicity rate was determined using the 
following formula: cytotoxicity (%) = 100 - ((At-Ab)/ 
(Ac-Ab)) × 100, where At = Absorbance value of the 
test compound, Ab= Absorbance value of the blank 
and Ac=Absorbance value of the negative control. 
Statistical analysis: Statistical analyses and graphical 
representation of data were carried out using 
GraphPad Prism version 6.00 (GraphPad Software). 
Data were presented as mean±standard deviation (SD) 
of the mean of at least three independent experiments. 
Statistical significance was calculated using a 
multiple comparison t test. P-values less than 0.05 
were considered to be statistically significant. 
Results 
In the present study, a dose-response experiment was 
performed to measure the in vitro cytotoxic activity of 
MMAE against SKBR3 and HEK293 cells (Figure 1). 
The cells were treated for 72 hours with MMAE at 
concentrations ranging from 0.002048 to 4000 nM. 
Cells with no treatment were used as negative 
controls. As shown in Figures 2A and 3A, 
microscopic observations demonstrated that MMAE 
was able to significantly induce cell death in both 
SkBr3 and HEK293 cell lines, compared to untreated 
cells.  
MTT was used to determine the cytotoxic effects of 
MMAE on breast and kidney cell lines. As shown in 
Figure 2B, proliferation of SKBR3 cells was 
significantly inhibited by MMAE at concentrations 
ranging from 0.01024 to 4000 nM, as compared with 
cells with no treatment. MMAE exhibited a 
significant increase in cell death (p<0.0001) at a 
concentration of 4µM with an inhibition rate of 
88.81% ± 4.38. A concentration of MMAE showing 
50% reduction in cell viability (IC50 [half maximal 
inhibitory concentration] values) was calculated to be 
3.27 ± 0.42 nM in SKBR3 cell population. The effect 
of MMAE was also investigated in the HEK293 cell 
line. As illustrated in Figure 3B, MMAE was also 
able to significantly inhibit HEK293 cell proliferation 
at concentrations ranging from 0.0512 to 4000 nM, 
compared with untreated cells. MMAE displayed 
significantly increased cell death at a concentration of 
4 µM (88.79% ± 2.61), as compared with untreated 
cells (p<0.0001). Dose–response experiments showed 
that the IC50 value of MMAE was 4.24 ± 0.37 nM in 
HEK293 cell population. The ability of MMAE to kill 
both SKBR3 and HEK293 cell lines significantly 
 
 
Figure 1. Schematic diagram of the experimental procedure to study the cytotoxic potential of MMAE on SKBR3 and HEK293 cell lines. 
After cell seeding, cells were treated with various concentrations of the drug. Following a 72-hour incubation, the MTT assay was carried out 
to evaluate cell viability in the presence and absence of the drug. 
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increased when compared with untreated cells 
(p<0.0001). The concentrations producing 50% 
growth inhibition potently suppressed proliferation of 
SkBr3 and HEK293 cells.  
Further investigation showed that MMAE, although 
displaying a significant cytotoxic potential against 
both cell lines, exhibits a higher cytotoxic effect on 
SKBR3 cells when compared with the HEK293 cell 
line, as depicted in Figure 4. The SKBR3 cell line was 
demonstrated to be more sensitive to MMAE cell 
killing than the HEK293 cell line. Our findings 
revealed that SKBR3 had a significantly increased 
cell death rate at concentrations of 0.256 (P<0.05) and 
1.28 (P<0.01) nM, when compared with that of 
HEK293. In addition, lower concentrations of MMAE 
showed more increased cell death in SKBR3 as 
compared with HEK293 (Figures 2 and 3). 
 
 
Figure 2. Effects of MMAE on the proliferation of the SKBR3 cell line. A) Microscopic observation was performed during the treatment. 
The upper and lower panels indicate cells receiving no treatment or treated with MMAE (6.4 nM), respectively. B) Cell viability was 
measured using the MTT assay after a 72-hour exposure period. Different concentrations (2.048 pM to 4 μM) of MMAE were assessed 
on the cell line, and the cytotoxcity rate was calculated as described in “Materials and Methods”. The data represent the mean and the 




Figure 3. The effects of MMAE on the proliferation of the HEK293 cell line. A) Microscopic observation was carried out during the 
treatment. The upper and lower panels represent cells receiving no treatment or treated with MMAE (6.4 nM), respectively. B) Cell 
viability was evaluated using the MTT assay after a 72-hour exposure period. Different concentrations (2.048 pM to 4 μM) of MMAE were 
assessed on the cell line, and the cytotoxcity rate was calculated as described in “Materials and Methods”. The data represent the mean and 
the error bars indicate standard deviation (SD) of three independent experiments. 
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Discussion 
In the present study, we investigated the cytotoxicty 
activity of MMAE, a synthetic antineoplastic agent, 
on two kinds of cancer cell lines. Results from our 
study showed that MMAE is highly cytotoxic against 
human cancer cell lines at nanomolar concentrations, 
consistent with our previous study on MDA-MB-468 
and MDA-MB-453 cells
23
. We also assessed the IC50 
of MMAE for SKBR3 and HEK293 cell lines, 
showing that MMAE has a higher IC50 value for 
HEK293 compared with SKBR3. There are no reports 
to date specifically assessing MMAE effects on 
SKBR3 and HEK293 cell lines. However, some 
studies assessed the effect of MMAE, in addition to 
dolastatine 10 and auristatin E, on a variety of cancer 
cell lines
19,20,22
. In a study carried out in 1990, 
Kalemkerian GP et al. showed that dolastatin 10 has 
potent growth inhibitory activity against four SCLC 
(small cell lung cancer) cell lines (NCI-H69, -H82, -
H446, -H510) with IC50 values ranging from 0.032 to 
0.184 nM
3
. A study conducted on a panel of seven 
human lymphoma cell lines demonstrated that the 
average IC50 value of auristatin E was 1.4 nM
19,20
. In 
2015, Burns KE et al. demonstrated that MMAE has 
potent cytotoxic activity against the HeLa cell with 
IC50 value of 4nM. In addition, they reported that 
MDA-MB-231 cells might be resistant to MMAE 
when compared with HeLa cells
24
. In 2016, Li H et al. 
showed that MMAE has a potent antitumor activity 
on NCI-N87Li H and BGC-823 cell lines, exhibiting 
IC50 values of 7.7 and 9.1 ng/ml
22
. Consistent with 
above-mentioned studies, we demonstrated that 
MMAE has the ability to induce cell death in SKBR3 
and HEK293. However, HEK293 seems to be less 
sensitive to MMAE treatment, as shown by lower 
cytotoxicity. We found that HEK293 has a higher 
IC50 value (4.24 ± 0.37 nM) compared with SKBR3 
(3.27 ± 0.42 nM). This may be due to the higher 
resistance of HEK293 cells to MMAE as compared 
with that of SKBR3 cells (Figure 4), because of 
upregulation of multidrug resistance (MDR) genes, 
key components of drug resistance in multiple 
cancers. In agreement with our findings, O'Brien C et 
al. demonstrated the resistance to MMAE in some 
cell lines. They showed that cell lines with the basal-
like gene expression profile had lower average IC50 
values and were more sensitive to MMAE than 
luminal or HER2-amplified cell lines. Overexpression 
 
 
Figure 4. Comparison of the cytotoxic activity of MMAE on SKBR3 and HEK293 cell lines. The percentages for the cell viability of MMAE-
treated cells were normalized to that of untreated control cells. After normalization, the effect of MMAE on the two cell lines was compared 
(* = P ≤ 0.05, and ** = P ≤ 0.01). 
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of ABCC3 (ATP binding cassette subfamily C 
member 3) was reported to be the main cause of in 
vitro MDR
25
. In 2015, Chen R et al.
26
 reported that 
MMAE resistance might be due to altered 
intracellular accumulation of MMAE after drug 
internalization. In fact, MMAE can be actively 
pumped out of the cell by P-glycoprotein or other 
transporters. However, auristatins have an IC50 that is 
52- and 197-fold more toxic than that of the clinically 




potent cytotoxic microtubule inhibitors that are 
clinically used as payloads in ADCs
27
. MMAE, as a 
synthetic analog, contains a secondary amine at its N-
terminus that could be attached to a linker and 
subsequently conjugated to monoclonal antibodies
13
. 
Although this potent drug is currently being used as 
payloads in ADC synthesis
13,15,16,28
, determining cell 
sensitivity or resistance of tumor cell lines to MMAE 
can help design more highly selective targeted 
therapeutics. To date, the drug MMAE has been 
widely used to construct various ADCs. The MMAE-
based ADCs has been widely utilized in the clinic 
trials
29





. More recently, the US FDA 
has approved a vc-MMAE-containing ADC, 
brentuximab vedotin (Adcetris®), to treat CD30-





It is well established that a wide variety of small 
molecules applying in ADC development represent 
significant cytotoxic and chemopreventive properties. 
The present study provides evidence that in-vitro 
cytotoxic activity of MMAE dose-dependently 
inhibits the proliferation of SKBR3 and HEK293 cell 
lines. However, further studies on primary cultures 
are a valuable alternative to clarify the cytotoxic 
activity of MMAE. 
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